Severance Hospital, Yonsei University

Seoul 3722

6 studies enrolling now · 41 studies all time

What they study most

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Advanced Cancer, Advanced Malignant Neoplasm, Advanced Solid Tumor, Advanced Solid Tumors, Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Antibody-mediated Rejection, Biliary Tract Cancer, Breast Cancer, Cholangiocarcinoma, Chronic Hepatitis B, Colitis, Ulcerative

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Recruiting now
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
• BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours — Recruiting now
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 — Recruiting now
• A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) — Recruiting now
• A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors — Recruiting now
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — Running, not enrolling
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Running, not enrolling
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] — Running, not enrolling
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) — Completed
• Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma — Completed
• A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) — Completed
• Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) — Running, not enrolling
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — Stopped early
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) — Stopped early
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF — Completed
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) — Completed
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Phase I/II Study of Avelumab in Pediatric Cancer Participants — Stopped early
• Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors — Completed
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) — Stopped early
• Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) — Completed
• A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. — Completed
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease — Completed
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease — Completed
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early
• An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Phase II Study of M2951 in SLE — Stopped early
• A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) — Stopped early
• Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma — Completed